CASP9 and myocardial infarction: Consistent with the results in vitro, ZYZ-488 suppressed the cleavage ratio of caspase-9 [33.9 mg/kg (2.00 ± 0.07%versus 2.34 ± 0.17%), 67.8 mg/kg (1.59 ± 0.07% versus 2.34 ± 0.17%)] and the subsequent activation of caspase-3 [33.9 mg/kg (2.92 ± 0.36% versus 7.64 ± 0.77%), 67.8 mg/kg (3.38 ± 0.44% versus 7.64 ± 0.77%)] after myocardial infarction injury (P < 0.05).